These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 16423422

  • 1. A peptide competing with VEGF165 binding on neuropilin-1 mediates targeting of a chlorin-type photosensitizer and potentiates its photodynamic activity in human endothelial cells.
    Tirand L, Frochot C, Vanderesse R, Thomas N, Trinquet E, Pinel S, Viriot ML, Guillemin F, Barberi-Heyob M.
    J Control Release; 2006 Mar 10; 111(1-2):153-64. PubMed ID: 16423422
    [Abstract] [Full Text] [Related]

  • 2. Metabolic profile of a peptide-conjugated chlorin-type photosensitizer targeting neuropilin-1: an in vivo and in vitro study.
    Tirand L, Thomas N, Dodeller M, Dumas D, Frochot C, Maunit B, Guillemin F, Barberi-Heyob M.
    Drug Metab Dispos; 2007 May 10; 35(5):806-13. PubMed ID: 17283031
    [Abstract] [Full Text] [Related]

  • 3. Tissue distribution and pharmacokinetics of an ATWLPPR-conjugated chlorin-type photosensitizer targeting neuropilin-1 in glioma-bearing nude mice.
    Thomas N, Tirand L, Chatelut E, Plénat F, Frochot C, Dodeller M, Guillemin F, Barberi-Heyob M.
    Photochem Photobiol Sci; 2008 Apr 10; 7(4):433-41. PubMed ID: 18385885
    [Abstract] [Full Text] [Related]

  • 4. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A, Vassy R, Martin A, Lecouvey M, Di Benedetto M, Crépin M, Perret GY.
    Life Sci; 2006 Nov 17; 79(25):2370-81. PubMed ID: 16959272
    [Abstract] [Full Text] [Related]

  • 5. Peptide-conjugated chlorin-type photosensitizer binds neuropilin-1 in vitro and in vivo.
    Thomas N, Bechet D, Becuwe P, Tirand L, Vanderesse R, Frochot C, Guillemin F, Barberi-Heyob M.
    J Photochem Photobiol B; 2009 Aug 03; 96(2):101-8. PubMed ID: 19464192
    [Abstract] [Full Text] [Related]

  • 6. Photodynamic therapy targeting neuropilin-1: Interest of pseudopeptides with improved stability properties.
    Thomas N, Pernot M, Vanderesse R, Becuwe P, Kamarulzaman E, Da Silva D, François A, Frochot C, Guillemin F, Barberi-Heyob M.
    Biochem Pharmacol; 2010 Jul 15; 80(2):226-35. PubMed ID: 20380812
    [Abstract] [Full Text] [Related]

  • 7. Effect of hypericin-mediated photodynamic therapy on the expression of vascular endothelial growth factor in human nasopharyngeal carcinoma.
    Bhuvaneswari R, Gan YY, Yee KK, Soo KC, Olivo M.
    Int J Mol Med; 2007 Oct 15; 20(4):421-8. PubMed ID: 17786271
    [Abstract] [Full Text] [Related]

  • 8. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts.
    Peng Q, Warloe T, Moan J, Godal A, Apricena F, Giercksky KE, Nesland JM.
    Cancer Res; 2001 Aug 01; 61(15):5824-32. PubMed ID: 11479222
    [Abstract] [Full Text] [Related]

  • 9. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG, Kim TD, Li G, Yoon WH, Chae CB.
    Clin Cancer Res; 2005 Apr 01; 11(7):2651-61. PubMed ID: 15814646
    [Abstract] [Full Text] [Related]

  • 10. Interest of RGD-containing linear or cyclic peptide targeted tetraphenylchlorin as novel photosensitizers for selective photodynamic activity.
    Frochot C, Di Stasio B, Vanderesse R, Belgy MJ, Dodeller M, Guillemin F, Viriot ML, Barberi-Heyob M.
    Bioorg Chem; 2007 Jun 01; 35(3):205-20. PubMed ID: 17223161
    [Abstract] [Full Text] [Related]

  • 11. New Peptide-Conjugated Chlorin-Type Photosensitizer Targeting Neuropilin-1 for Anti-Vascular Targeted Photodynamic Therapy.
    Kamarulzaman EE, Gazzali AM, Acherar S, Frochot C, Barberi-Heyob M, Boura C, Chaimbault P, Sibille E, Wahab HA, Vanderesse R.
    Int J Mol Sci; 2015 Oct 12; 16(10):24059-80. PubMed ID: 26473840
    [Abstract] [Full Text] [Related]

  • 12. Response surface methodology: an extensive potential to optimize in vivo photodynamic therapy conditions.
    Tirand L, Bastogne T, Bechet D, Linder M, Thomas N, Frochot C, Guillemin F, Barberi-Heyob M.
    Int J Radiat Oncol Biol Phys; 2009 Sep 01; 75(1):244-52. PubMed ID: 19604651
    [Abstract] [Full Text] [Related]

  • 13. High expression of GADD-45alpha and VEGF induced tumor recurrence via upregulation of IL-2 after photodynamic therapy using NPe6.
    Ohtani K, Usuda J, Ichinose S, Ishizumi T, Hirata T, Inoue T, Maehara S, Imai K, Kubota M, Tsunoda Y, Yamada M, Tsutsui H, Yamada K, Kuroiwa Y, Furukawa K, Okunaka T, Kato H.
    Int J Oncol; 2008 Feb 01; 32(2):397-403. PubMed ID: 18202762
    [Abstract] [Full Text] [Related]

  • 14. Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo.
    Kirveliene V, Grazeliene G, Dabkeviciene D, Micke I, Kirvelis D, Juodka B, Didziapetriene J.
    Cancer Chemother Pharmacol; 2006 Jan 01; 57(1):65-72. PubMed ID: 16001168
    [Abstract] [Full Text] [Related]

  • 15. Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex.
    Starzec A, Ladam P, Vassy R, Badache S, Bouchemal N, Navaza A, du Penhoat CH, Perret GY.
    Peptides; 2007 Dec 01; 28(12):2397-402. PubMed ID: 17983687
    [Abstract] [Full Text] [Related]

  • 16. Studies on preparation and photodynamic mechanism of chlorin P6-13,15-N-(cyclohexyl)cycloimide (Chlorin-H) and its antitumor effect for photodynamic therapy in vitro and in vivo.
    Yan YJ, Zheng MZ, Chen ZL, Yu XH, Yang XX, Ding ZL, Xu L.
    Bioorg Med Chem; 2010 Sep 01; 18(17):6282-91. PubMed ID: 20691601
    [Abstract] [Full Text] [Related]

  • 17. Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer.
    Solban N, Selbo PK, Sinha AK, Chang SK, Hasan T.
    Cancer Res; 2006 Jun 01; 66(11):5633-40. PubMed ID: 16740700
    [Abstract] [Full Text] [Related]

  • 18. Decrease of endogenous vascular endothelial growth factor may not affect glioma cell proliferation and invasion.
    Hong X, Jiang F, Kalkanis SN, Zhang ZG, Zhang X, Zheng X, Mikkelsen T, Jiang H, Chopp M.
    J Exp Ther Oncol; 2007 Jun 01; 6(3):219-29. PubMed ID: 17552362
    [Abstract] [Full Text] [Related]

  • 19. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.
    Clin Cancer Res; 2008 Apr 01; 14(7):2210-9. PubMed ID: 18381963
    [Abstract] [Full Text] [Related]

  • 20. Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis.
    Héroult M, Bernard-Pierrot I, Delbé J, Hamma-Kourbali Y, Katsoris P, Barritault D, Papadimitriou E, Plouet J, Courty J.
    Oncogene; 2004 Mar 04; 23(9):1745-53. PubMed ID: 15001987
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.